Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 24, 2007

Inovio Allies with the NCI and International AIDS Vaccine Initiative to Research Its DNA Delivery Tool

  • Inovio Biomedical reports that its wholly owned subsidiary, Genetronics, entered into separate deals with the NCI and International AIDS Vaccine Initiative (IAVI), to evaluate Inovio's electroporation technology for the delivery of DNA vaccines. The technology is designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.

    The collaboration with the NCI, being conducted under a CRADA, will assess novel HIV constructs in nonhuman primates, cytokine genes as vaccine adjuvants, and possibly anticancer therapies delivered using Inovio's electroporation-mediated DNA delivery tool.

    The IAVI partnership will focus on optimizing HIV vaccine design. Experimental HIV vaccines will be screened in preclinical models to select the most efficacious design to advance to clinical testing.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »